Sequenom Appoints Paul Maier as Interim CFO

Sequenom, a life sciences company, has appointed Paul V. Maier as interim chief financial officer (CFO), reporting directly to the company’s interim chief executive officer (CEO) and chairman of the board, Harry Hixson, Jr.

Maier has been an independent financial consultant since February 2007. He served as senior vice president and CFO of Ligand Pharmaceuticals from 1992 until January 2007, where he helped build Ligand from a venture stage boutique company to a commercial, integrated biopharmaceutical organisation. During his tenure at Ligand, Maier helped to raise over US$1bn in equity and debt financings. Prior to Ligand, Maier spent six years in various management and finance positions at ICN Pharmaceuticals.

Comments are closed.